Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gynecologic 1CNS 1Breast 1

Conditions

Severe Combined Immunodeficiency 1Neuroblastoma 1Neoplasms 1Mucopolysaccharidosis I 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Prospective Studies × Other hematologic neoplasm × Clear all
NCT00695279 2024-10-30

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

St. Jude Children's Research Hospital

Completed
41 enrolled
CNSOther hematologic neoplasm

Mucopolysaccharidosis I, Neoplasms, Neuroblastoma, Severe Combined Immunodeficiency, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡